← Leaderboards
Ivan Zanoni
Boston Children'S Hospital
$12,849,670
Attributed
$15,245,923
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.7M · FY2016–25$5M$3.8M$2.5M$1.3M$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,245,923 · 4
By mechanism
R01$15,245,923 · 4
Top collaborators
- Scott B Snapper7 shared
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsImmunePathogenImmune ResponseMouse ModelPlayInflammatoryInflammationSignal TransductionPattern Recognition ReceptorMediatingTissuesTherapeutic InterventionResponseImmune SystemMolecularAffectPreventProductionMycosesPathway InteractionsGenetic TranscriptionInterferon Type IiLigands
Grant awards (25)
Type III interferon Control of Mucosal Immunity$777,421
R01 · FY2025 · DK · contact PI
Development of a novel adjuvant strategy enabled by modulation of the physical properties of fungal mannans$733,725
R01 · FY2025 · AI · contact PI
Macrophage immunometabolism controls septic shock$639,636
R01 · FY2025 · AI · contact PI
Innate control of the inflammatory process during fungal infections$495,632
R01 · FY2025 · AI · contact PI
Type III interferon Control of Mucosal Immunity$746,324
R01 · FY2024 · DK · contact PI
Development of a novel adjuvant strategy enabled by modulation of the physical properties of fungal mannans$743,329
R01 · FY2024 · AI · contact PI
Macrophage immunometabolism controls septic shock$646,238
R01 · FY2024 · AI · contact PI
Innate control of the inflammatory process during fungal infections$504,871
R01 · FY2024 · AI · contact PI
Type III interferon Control of Mucosal Immunity$777,421
R01 · FY2023 · DK · contact PI
Development of a novel adjuvant strategy enabled by modulation of the physical properties of fungal mannans$748,825
R01 · FY2023 · AI · contact PI
Macrophage immunometabolism controls septic shock$631,476
R01 · FY2023 · AI · contact PI
Innate control of the inflammatory process during fungal infections$513,838
R01 · FY2023 · AI · contact PI
Development of a novel adjuvant strategy enabled by modulation of the physical properties of fungal mannans$751,928
R01 · FY2022 · AI · contact PI
Innate control of the inflammatory process during fungal infections$522,545
R01 · FY2022 · AI · contact PI
Development of a novel adjuvant strategy enabled by modulation of the physical properties of fungal mannans$777,874
R01 · FY2021 · AI · contact PI
Innate control of the inflammatory process during fungal infections$531,000
R01 · FY2021 · AI · contact PI
Type III interferon Control of Mucosal Immunity$622,835
R01 · FY2020 · DK
Innate control of the inflammatory process during fungal infections$442,500
R01 · FY2020 · AI · contact PI
Type III interferon Control of Mucosal Immunity$622,835
R01 · FY2019 · DK
Innate control of the inflammatory process during fungal infections$442,500
R01 · FY2019 · AI · contact PI
Type III interferon Control of Mucosal Immunity$622,835
R01 · FY2018 · DK
Innate control of the inflammatory process during fungal infections$442,500
R01 · FY2018 · AI · contact PI
Type III interferon Control of Mucosal Immunity$622,835
R01 · FY2017 · DK
Innate control of the inflammatory process during fungal infections$442,500
R01 · FY2017 · AI · contact PI
Innate control of the inflammatory process during fungal infections$442,500
R01 · FY2016 · AI · contact PI